Melanoma is a cancer that exhibits one of the most aggressive and heterogeneous features.
The incidence rate escalates. A high number of clones harboring various mutations …

The discovery of the role of the RAS/RAF/MEK/ERK pathway in melanomagenesis and its
progression have opened a new era in the treatment of this tumor. Vemurafenib was the first …

Mutational activation of KRAS promotes the initiation and progression of cancers, especially
in the colorectum, pancreas, lung, and blood plasma, with varying prevalence of specific …

Purpose The prevalence of BRAF, NRAS, and p16CDKN2A mutations during melanoma
progression remains inconclusive. We investigated the prevalence and distribution of …

Somatic mutations in noncoding sequences are poorly explored in cancer, a rare exception
being the recent identification of activating mutations in TERT regulatory DNA. Although this …

Melanoma, a cancer of the skin, arises from transformed melanocytes. Melanoma has the
highest mutational burden of any cancer partially attributed to UV induced DNA damage …

The rationale for using small molecule inhibitors of oncogenic proteins as cancer therapies
depends, at least in part, on the assumption that metastatic tumors are primarily clonal with …

In recent years, melanoma research has undergone a renaissance. What was once viewed,
at least in the metastatic setting, as an intractable and untreatable disease is now revealing …

Human lung adenocarcinomas (LUAD) contain mutations in EGFR in∼ 15% of cases and in
KRAS in∼ 30%, yet no individual adenocarcinoma appears to carry activating mutations in …

We assessed the utility of droplet digital PCR (ddPCR) to evaluate the potential of using
circulating tumour DNA (ctDNA) as a post therapy monitoring tool in melanoma by …